Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

NCT00243659 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

BIOLOGICAL: ReFacto AF

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer